Compare Global X Data Center & Digital Infra ETF (DTCR) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global X Data Center & Digital Infra ETF vs Tango Therapeutics Inc. — how do they compare? Global X Data Center & Digital Infra ETF trades at $26.08 (market cap $2.11B), while Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B). The key difference: Tango Therapeutics Inc. is the larger of the two by market cap, and Global X Data Center & Digital Infra ETF is more actively traded (655,653 versus 9,619,106). Which is the better fit depends on your goals — on Pluang, investors hold Global X Data Center & Digital Infra ETF for 17 Days and Tango Therapeutics Inc. for 0 Days on average.
| DTCR | TNGX | |
|---|---|---|
Market Cap | $2.11B | $3.75B |
Volume | 655,653 | 9,619,106 |
Sector | Sector/Thematic | Health |
52-Week High | $32.46 | $32.90 |
52-Week Low | $19.73 | $7.50 |
Typical Hold Time | 17 Days | 0 Days |
Enterprise Value | — | $2.77B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DTCR trades at $27.33, down 1.44% on the day, with technical indicators showing a bullish trend from moving averages while oscillators remain neutral. Recent news highlights DTCR's position as a key ETF for AI infrastructure exposure, with coverage emphasizing its blend of real estate stability and growth from digital infrastructure sectors. The ETF has gained attention as a picks-and-shovels play in the AI boom.
The outlook for DTCR appears favorable given sustained AI infrastructure investment, though risks include sector volatility and interest rate sensitivity. Analyst sentiment remains positive with buy recommendations citing long-term growth potential from diversified technology and real estate holdings.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Global X Data Center & Digital Infra ETF
Global X Data Center & Digital Infrastructure ETF seeks exposure to companies involved in data centers and digital infrastructure. Its holdings span areas such as digital infrastructure, networking, and related real estate.
Read more on DTCR →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
